Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 509-518

  Merten, Julianna A ^a   Shapiro, Jamie F ^b   Gulbis, Alison M ^c   Rao, Kamakshi V ^d   Bubalo, Joseph ^e   Lanum, Scott ^f   Engemann, Ashley Morris ^g   Shayani, Sepideh ^h   Williams, Casey ⁱ   Leather, Helen ^j   Walsh Chocolaad, Tracey ^k  

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ SANFORD RESEARCH   (United States)

^j UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

Collaborative drug therapy management; Hematopoietic cell transplantation; Medication Therapy Management; National Marrow Donor Program; Pharmaceutical services; Physician capacity

Indexed keywords

WARFARIN;

ALGORITHM; COLLABORATIVE PRACTICE AGREEMENT; COST EFFECTIVENESS ANALYSIS; DRUG SURVEILLANCE PROGRAM; GRAFT RECIPIENT; HEALTH CARE MANAGEMENT; HEALTH INSURANCE; HEALTH SERVICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEDICAL PRACTICE; MEDICATION THERAPY MANAGEMENT; MEDICOLEGAL ASPECT; PATIENT ATTITUDE; PATIENT CARE; PATIENT SATISFACTION; PERSONNEL MANAGEMENT; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; REIMBURSEMENT; REVIEW;

COOPERATIVE BEHAVIOR; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PARTNERSHIP PRACTICE; PHARMACISTS; PHYSICIANS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84875488797     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.022     Document Type: Review

References (66)

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. Center for International Blood and Marrow Transplant Research. Available at:. Accessed July 15, 2012. http://www.cibmtr.org.
2. Schriber J.R., Anasetti C., Heslop H.E., et al. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Transplant 2010, 16:595-597.
3. Majhail N.S., Murphy E.A., Denzen E.M., et al. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Transplant 2012, 18:172-182.
4. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:348-371.
5. Bootman JL, Cronewett LR, Bates DW, et al. Preventing Medication Errors. Institute of Medicine of the National Academies. Available at:. Accessed July 15, 2012. http://www.iom.edu/%7e/media/Files/Report%2520Files/2006/Preventing-Medication-Errors-Quality-Chasm-Series/medicationerrorsnew.pdf.
6. Valgus J.M., Faso A., Gregory K.M., et al. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health Syst Pharm 2011, 68:613-619.
7. Punekar Y., Lin S.W., Thomas J. Progress of pharmacist collaborative practice: status of state laws and regulations and perceived impact of collaborative practice. J Am Pharm Assoc 2003, 43:503-510.
8. Dinardo J. How to set up a collaborative practice. Drug Topics available at:. Accessed May 15, 2012. http://drugtopics.modernmedicine.com/drugtopics/Legal+News/How-to-set-up-a-collaborative-practice/ArticleStandard/Article/detail/461191.
9. Hammond R.W., Schwartz A.H., Campbell M.J., et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy 2003, 23:1210-1225.
10. Practice Advisory on Collaborative Drug Therapy Management. Academy of Managed Care Pharmacy. Available at:. Accessed September 16, 2012. http://www.amcp.org/WorkArea/DownloadAsset.aspx%3fid%3d14710.
11. Sessions J.K., Valgus J., Barbour S.Y., et al. Role of oncology clinical pharmacists in light of the oncology workforce study. J Oncol Pract 2010, 6:270-272.
12. Brands A. Treating Ambulatory Patients. US Pharmacist 1977, 2:70-74.
13. Erickson S.H. Primary care by a pharmacist in an outpatient clinic. Am J Hosp Pharm 1977, 34:1086-1090.
14. Bernstein B.J., Blanchard L.M. Economic and clinical impact of a pharmacy-based filgrastim protocol in oncology patients. Am J Health Syst Pharm 1999, 56:1330-1333.
15. Martin J.K., Norwood M.B. Pharmacist management of antiemetic therapy under protocol in an oncology clinic. Am J Hosp Pharm 1988, 45:1322-1328.
16. Gilreath J.A., Sageser D.S., Jorgenson J.A., et al. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008, 6:577-584.
17. Horne A.L., Dapolite L.A. Protocol for pharmacist management of antineoplastic drug-induced adverse effects in outpatients. Am J Health Syst Pharm 1997, 54:680-683.
18. Shah S., Dowell J., Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 2006, 40:1527-1533.
19. Chung C., Collins A., Cui N. Development and implementation of an interdisciplinary oncology program in a community hospital. Am J Health Syst Pharm 2011, 68:1740-1747.
20. Watkins J.L., Landgraf A., Barnett C.M., et al. Evaluation of pharmacist-provided medication therapy management services in an oncology ambulatory setting. J Am Pharm Assoc 2012, 52:170-174.
21. Burzynski J.A., Craver L.F., Geerdes P.A., et al. Impact of a pharmacist in the outpatient allogeneic stem cell transplant clinic. Biol Blood Marrow Transplant 2009, 15:33-34. (abstr 83).
22. Gilberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U.S. Sugeon General. Office of the Chief Pharmacist. US Public Health Service. Available at:. Accessed September 16, 2012. http://www.pharmacist.com/sites/default/files/files/USPHS_Report_USSG_1(1).pdf.
23. Medicare and Medicaid Programs; Reform of Hospital and Critical Access Hospital Conditions of Participation. Fed Regist 2012, 77:29034-29076. To be codified at 42 CFR §482 and §485.
24. Thomas J., Bharmal M., Lin S.W., et al. Survey of pharmacist collaborative drug therapy management in hospitals. Am J Health Syst Pharm 2006, 63:2489-2499.
25. Delineation of Clinical Privileges Clinical Pharmacy. United States Army. Available at:. Accessed July 15, 2012. http://www.apd.army.mil/pub/eforms/pdf/a5440_38.pdf.
26. New Mexico Administrative Code § 18.16.19.4.17 NMAC. Pharmacist Clinician.
27. Hall D., Buchanan J., Helms B., et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy 2011, 31:686-694.
28. North Carolina Adminstrative Code § 46.3101. Clinical Pharmacist Practitioner.
29. Barbanel D., Eldridge S., Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. Thorax 2003, 58:851-854.
30. Ellis S.L., Carter B.L., Malone D.C., et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of managed pharmaceutical care on resource utilization and outcomes in veterans affairs medical centers. Pharmacotherapy 2000, 20:1508-1516.
31. Bogden P.E., Koontz L.M., Williamson P., et al. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 1997, 12:158-164.
32. Carter B.L., Barnette D.J., Chrischilles E., et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997, 17:1274-1285.
33. Erhun W.O., Agbani E.O., Bolaji E.E. Positive benefits of a pharmacist-managed hypertension clinic in Nigeria. Public Health 2005, 119:792-798.
34. Jaber L.A., Halapy H., Fernet M., et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996, 30:238-243.
35. Scott D.M., Boyd S.T., Stephan M., et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm 2006, 63:2116-2122.
36. Jackson S.L., Peterson G.M., Vial J.H., et al. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med 2004, 256:137-144.
37. Valgus J., Jarr S., Schwartz R., et al. Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting. J Oncol Prac 2010, 6:e1-e4.
38. Bernard S., LC, Usher B., et al. Symptom assessment tools used in a hospital-based pain and symptom care program at the University of North Carolina: A novel proxy rating. Proc Am Soc Clin Oncol 2006, 24:487s. (abstr 8579).
39. Read H., Ladds S., Rhodes B., et al. The impact of a supplementary medication review and counselling service within the oncology outpatient setting. Br J Ca 2007, 96:744-751.
40. Chisholm M.A., Mulloy L.L., Jagadeesan M., et al. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant 2001, 15:330-336.
41. Chisholm-Burns M.A., Spivey C.A., Garrett C., et al. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. Patient Prefer Adherence 2008, 2:287-292.
42. Talley C.R. Prescribing authority for pharmacists. Am J Health Syst Pharm 2011, 68:2333.
43. Zarowitz B.J., Miller W.A., Helling D.K., et al. Optimal medication therapy prescribing and management: meeting patients' needs in an evolving health care system. Pharmacotherapy 2010, 30:350e-359e.
44. Koecheler J.A., Abramowitz P.W., Swim S.E., et al. Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. Am J Hosp Pharm 1989, 46:729-732.
45. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual Chapter 6 - Part D Drugs and Formulary Requirements. Available at:. Accessed September 27, 2012. http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/Chapter6.pdf.
46. Alkhateeb F.M., Unni E., Latif D., et al. Physician attitudes toward collaborative agreements with pharmacists and their expectations of community pharmacists' responsibilities in West Virginia. J Am Pharm Assoc 2009, 49:797-800.
47. McBane S., Trewet C.B., Havican S.N., et al. Tenets for developing quality measures for ambulatory clinical pharmacy services. Pharmacotherapy 2011, 31:115e-134e.
48. Whitmer K., Pruemer J., Wilhelm C., et al. Development of an outpatient oncology symptom management clinic. Clin J Oncol Nurs 2011, 15:175-179.
49. Bejanyan N., Bolwell B.J., Lazaryan A., et al. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). Biol Blood Marrow Transplant 2012, 18:874-880.
50. Watanabe N., Matsumoto K., Muramatsu H., et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. Bone Marrow Transplant 2010, 45:116-1166.
51. Hammer M.J., Casper C., Gooley T.A., et al. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009, 15:344-351.
52. Majhail N.S., Challa T.R., Mulrooney D.A., et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:1100-1107.
53. Griffith M.L., Savani B.N., Boord J.B. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010, 116:1197-1204.
54. Henderson K.C., Hindman J., Johnson S.C., et al. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care STDS 2011, 25:221-228.
55. Kraemer D.F., Kradjan W.A., Bianco T.M., et al. A randomized study to assess the impact of pharmacist counseling of employer-based health plan beneficiaries with diabetes: the EMPOWER study. J Pharm Pract 2012, 25:169-179.
56. Favier M., de Cazanove F., Bressolle F., et al. Pharmacist development and use of antiemetic protocols. Am J Health Syst Pharm 1995, 52:319-320.
57. Lothian S.T., Fotis M.A., von Gunten C.F., et al. Cancer pain management through a pharmacist-based analgesic dosing service. Am J Health Syst Pharm 1999, 56:1119-1125.
58. Dennehy E.B., Suppes T., Rush A.J., et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas medication algorithm project. Psychol Med 2005, 35:1695-1706.
59. Erickson J.L., Velasco J.M., Hieken T.J. Compliance with melanoma treatment guidelines in a community teaching hospital: time trends and other variables. Ann Surg Oncol 2008, 15:1211-1217.
60. Maldonado A.Q., Seiger T.C., Urann C.L., et al. Billing for outpatient transplant pharmacy services. Am J Health Syst Pharm 2012, 69:144-147.
61. Sachdev G.P. Billing for pharmacists' services provided to ambulatory care patients. Am J Health Syst Pharm 2012, 69:105.
62. Glickman S.W., Boulding W., Manary M., et al. Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. Circ Cardiovasc Quality Outcomes 2010, 3:188-195.
63. Morisky D.E., Ang A., Krousel-Wood M., et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008, 10:348-354.
64. Roberts K.J. Physician-patient relationships, patient satisfaction, and antiretroviral medication Adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS 2002, 16:43-50.
65. McKee M., Frei B.L., Garcia A., et al. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract 2011, 17:387-394.
66. Hlubocky J.M., Stuckey L.J., Schuman A.D., et al. Evaluation of a transplantation specialty pharmacy program. Am J Health Syst Pharm 2012, 69:340-347.